On September 10, 2024, WuXi Biologics submitted a new disclosure report, disclosing the changes in its issued shares and treasury shares. According to the report, from September 4 to September 10, 2024, the company issued a total of 192,340 new shares through share incentive plans or options granted to participants (excluding directors), at prices ranging from HKD 1.33 to HKD 2.64. In addition, between June 11 and September 10, 2024, the company repurchased a total of 28,150,000 shares at prices ranging from HKD 10.89 to HKD 11.03, and plans to cancel these shares. After the repurchase, the total number of issued shares of the company is 4,153,521,696. The company confirms that all share issuance and repurchase activities have been approved by the board of directors and are in compliance with relevant listing rules and regulations.

On September 10, 2024, WuXi Biologics submitted a new disclosure report, disclosing the changes in its issued shares and treasury shares. According to the report, from September 4 to September 10, 2024, the company issued a total of 192,340 new shares through share incentive plans or options granted to participants (excluding directors), at prices ranging from HKD 1.33 to HKD 2.64. In addition, between June 11 and September 10, 2024, the company repurchased a total of 28,150,000 shares at prices ranging from HKD 10.89 to HKD 11.03, and plans to cancel these shares. After the repurchase, the total number of issued shares of the company is 4,153,521,696. The company confirms that all share issuance and repurchase activities have been approved by the board of directors and are in compliance with relevant listing rules and regulations.